These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Using microRNA as an alternative treatment for hyperlipidemia and cardiovascular disease: cardio-miRs in the pipeline. Hennessy EJ; Moore KJ J Cardiovasc Pharmacol; 2013 Sep; 62(3):247-54. PubMed ID: 23743768 [TBL] [Abstract][Full Text] [Related]
25. Gene transfer strategies in tissue engineering. Bleiziffer O; Eriksson E; Yao F; Horch RE; Kneser U J Cell Mol Med; 2007; 11(2):206-23. PubMed ID: 17488473 [TBL] [Abstract][Full Text] [Related]
26. Antisense technologies have a future fighting neurodegenerative diseases. Seidman S; Eckstein F; Grifman M; Soreq H Antisense Nucleic Acid Drug Dev; 1999 Aug; 9(4):333-40. PubMed ID: 10463077 [TBL] [Abstract][Full Text] [Related]
27. Drugs made of RNA: development and application of engineered RNAs for gene therapy. Drude I; Dombos V; Vauléon S; Müller S Mini Rev Med Chem; 2007 Sep; 7(9):912-31. PubMed ID: 17897081 [TBL] [Abstract][Full Text] [Related]
28. Emerging Concepts for RNA Therapeutics for Inherited Retinal Disease. Moore SM; Skowronska-Krawczyk D; Chao DL Adv Exp Med Biol; 2019; 1185():85-89. PubMed ID: 31884593 [TBL] [Abstract][Full Text] [Related]
29. [Important contribution and necessity of stem cells scaffolds for regenerative medicine and the therapeutic applications]. Tabata Y Nihon Rinsho; 2008 May; 66(5):881-6. PubMed ID: 18464505 [TBL] [Abstract][Full Text] [Related]
32. Brothers in arms: DNA enzymes, short interfering RNA, and the emerging wave of small-molecule nucleic acid-based gene-silencing strategies. Bhindi R; Fahmy RG; Lowe HC; Chesterman CN; Dass CR; Cairns MJ; Saravolac EG; Sun LQ; Khachigian LM Am J Pathol; 2007 Oct; 171(4):1079-88. PubMed ID: 17717148 [TBL] [Abstract][Full Text] [Related]
33. Oligonucleotide-based gene therapy for cardiovascular disease: are oligonucleotide therapeutics novel cardiovascular drugs? Morishita R; Aoki M; Kaneda Y Curr Drug Targets; 2000 Jul; 1(1):15-23. PubMed ID: 11475534 [TBL] [Abstract][Full Text] [Related]
34. Nano and microcarriers to improve stem cell behaviour for neuroregenerative medicine strategies: Application to Huntington's disease. André EM; Passirani C; Seijo B; Sanchez A; Montero-Menei CN Biomaterials; 2016 Mar; 83():347-62. PubMed ID: 26802487 [TBL] [Abstract][Full Text] [Related]
35. Approaches for the sequence-specific knockdown of mRNA. Scherer LJ; Rossi JJ Nat Biotechnol; 2003 Dec; 21(12):1457-65. PubMed ID: 14647331 [TBL] [Abstract][Full Text] [Related]
36. Therapeutic potential and mechanism of action of oligonucleotides and ribozymes. Lavrovsky Y; Chen S; Roy AK Biochem Mol Med; 1997 Oct; 62(1):11-22. PubMed ID: 9367793 [TBL] [Abstract][Full Text] [Related]
37. Acquired and innate cardioprotection. Terzic A; Moore RL; Waldman SA J Appl Physiol (1985); 2007 Oct; 103(4):1436-7. PubMed ID: 17690193 [No Abstract] [Full Text] [Related]
39. Mesenchymal stem cells as the game-changing tools in the treatment of various organs disorders: Mirage or reality? Marofi F; Vahedi G; Hasanzadeh A; Salarinasab S; Arzhanga P; Khademi B; Farshdousti Hagh M J Cell Physiol; 2019 Feb; 234(2):1268-1288. PubMed ID: 30191962 [TBL] [Abstract][Full Text] [Related]
40. Gene delivery in tissue engineering and regenerative medicine. Fang YL; Chen XG; W T G J Biomed Mater Res B Appl Biomater; 2015 Nov; 103(8):1679-99. PubMed ID: 25557560 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]